Announcements Trials

Browse Landscape

Phase

Phase 1/2 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Pancreatic Neoplasms 1 Carcinoma, Medullary 1

Interventions

Carboplatin 79 pembrolizumab 64 Paclitaxel 64 Cyclophosphamide 47 Capecitabine 34 Doxorubicin 31 Taxes 28 130-nm albumin-bound paclitaxel 28 Albumin-Bound Paclitaxel 27 Gemcitabine 20 atezolizumab 18 Epirubicin 18 Cisplatin 18 Bevacizumab 18 olaparib 17 sacituzumab govitecan 15 Docetaxel 15 eribulin 14 toripalimab 13 durvalumab 13 camrelizumab 13 Drug Therapy 12 apatinib 9 Trastuzumab 9 Radiotherapy 9 Specimen Handling 8 Magnetic Resonance Spectroscopy 8 Biopsy 8 tislelizumab 7 talazoparib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Triple Negative Breast Neoplasms × yeast-CEA vaccine × Clear all

NCT03554109 2025-02-21

TNBC

ImmunityBio, Inc.

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡